Metastatic Esophageal Carcinoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB09037 | Pembrolizumab | Programmed cell death protein 1 | target |
| DB09037 | Pembrolizumab | Programmed cell death 1 ligand 1 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00041 | Aldesleukin | 1 | Terminated | 1 |
| DB00531 | Cyclophosphamide | 1 | Terminated | 1 |
| DB09037 | Pembrolizumab | 1 | Terminated | 1 |
| DB06599 | Lexatumumab | 1 / 2 | Active Not Recruiting | 1 |
| DB09074 | Olaparib | 1 / 2 | Active Not Recruiting | 1 |
| DB05578 | Ramucirumab | 1 / 2 | Active Not Recruiting | 1 |
| DB15676 | Balstilimab | 2 | Recruiting | 1 |
| DB16651 | Botensilimab | 2 | Recruiting | 1 |
| DB01229 | Paclitaxel | 2 | Recruiting | 1 |
| DB05578 | Ramucirumab | 2 | Recruiting | 1 |